AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Jul 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-07-09

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-09	Common Stock	M	11559	$8.61	Acquired	174763	Direct
2020-07-09	Common Stock	M	8850	$9.03	Acquired	183613	Direct
2020-07-09	Common Stock	M	6142	$10.04	Acquired	189755	Direct
2020-07-09	Common Stock	M	17896	$12.28	Acquired	207651	Direct
2020-07-09	Common Stock	S	44447	$15.9177	Disposed	163204	Direct
2020-07-10	Common Stock	M	28843	$5.13	Acquired	192047	Direct
2020-07-10	Common Stock	S	28843	$15.6514	Disposed	163204	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-09	Stock Options (right to buy)	$8.61	M	11559	Disposed	2025-01-02	Common Stock (11559)	Direct
2020-07-09	Stock Options (right to buy)	$9.03	M	8850	Disposed	2026-01-04	Common Stock (8850)	Direct
2020-07-09	Stock Options (right to buy)	$10.04	M	6142	Disposed	2029-01-02	Common Stock (6142)	Direct
2020-07-09	Stock Options (right to buy)	$12.28	M	17896	Disposed	2025-06-01	Common Stock (17896)	Direct
2020-07-10	Stock Options (right to buy)	$5.13	M	28843	Disposed	2027-01-03	Common Stock (28843)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $15.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.49 to $15.91 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All of the options were fully vested and exercisable as of the transaction date.

F5: As of July 9, 2020, 9,584 options were fully vested and exercisable and 51,657 remained unvested from this grant.

F6: As of July 10, 2020, 31,785 options were fully vested and exercisable and 8,836 remained unvested from this grant.